Stock Market Closing Highlights: Sensex adds 234 points, Nifty at 23,708; Smallcap shares outperform
Markets Today Highlights: Among the broader markets, small-cap shares outperformed others, with the Nifty Smallcap100 ending up 1.35 per cent
 "Stock Market, BSE, NSE, Nifty, Capital")
(Photo: Shutterstock)
9:18 AM
Stock Market LIVE Updates: Sensex up over 350 pts above 78,300 during open
Stock Market LIVE Updates: BSE Sensex was up over 350 points above 78,300 during open.
9:17 AM
Stock Market LIVE Updates: Nifty50 up over 100 pts above 23,700
Stock Market LIVE Updates: NSE Nifty50 was up over 100 poits above 23,700 during open.
9:15 AM
Stock Market LIVE Updates: A glance at broader market
Stock Market LIVE Updates: BSE Midcap and Smallcap flat in pre open
9:13 AM
Stock Market LIVE Updates: Here's a look at Sensex gainers and loser at close
Stock Market LIVE Updates: Sun Pharma, Infosys, Titan were among the top gainers on Sensex in pre open.
9:07 AM
Stock Market LIVE Updates: Nifty up over 50 pts above 23,650 in pre open
Stock Market LIVE Updates: NSE Nifty50 was up over 50 points above 23,650 in pre open.
9:05 AM
Stock Market LIVE Updates: Sensex down nearly 100 pts below 77,900 in pre open
Stock Market LIVE Updates: BSE Sensex was down nearly 100 points below 77,900 in pre open.
8:58 AM
The company's India operations witnessed revenue growth of approximately 41 per cent during Q3 FY2025 as compared to Q3 FY2024, led by very strong festive and wedding demand across both gold and studded categories. The quarter recorded healthy same-store-sales-growth of approximately 24 per cent, it added.
The company launched 24 Kalyan showrooms in India during the quarter, with a strong pipeline of showrooms set to open over the course of the current quarter. During the quarter it launched its first (Company Owned Company Operated) showroom in the US.
The company's digital-first jewellery platform, Candere, recorded a revenue growth of approximately 89 per cent during the recently concluded quarter as compared to the same period during the last year. It launched 23 Candere showrooms during Q3 FY 2025.
The company further said it plans to launch 30 Kalyan showrooms and 15 Candere showrooms in India during the current quarter, with an aim to stay ahead of its announced showroom roll-out plan of 80 Kalyan showrooms and 50 Candere showrooms in India for FY2025.
For FY 2026, the company has drawn up plans to launch 170 showrooms across Kalyan and Candere formats - 75 Kalyan showrooms (all FOCO) in non-south India, 15 Kalyan showrooms (all FOCO) across south India and international markets and 80 Candere showrooms in India.
Stock Market LIVE Updates: Kalyan Jewellers posts 39% rev growth in Q3; plans to add 30 Kalyan stores in Q4
Stock Market LIVE Updates: Kalyan Jewellers today informed that the recently concluded quarter recorded consolidated revenue growth of approximately 39 per cent when compared to the same period in the previous financial year.
The company's India operations witnessed revenue growth of approximately 41 per cent during Q3 FY2025 as compared to Q3 FY2024, led by very strong festive and wedding demand across both gold and studded categories. The quarter recorded healthy same-store-sales-growth of approximately 24 per cent, it added.
The company launched 24 Kalyan showrooms in India during the quarter, with a strong pipeline of showrooms set to open over the course of the current quarter. During the quarter it launched its first (Company Owned Company Operated) showroom in the US.
The company's digital-first jewellery platform, Candere, recorded a revenue growth of approximately 89 per cent during the recently concluded quarter as compared to the same period during the last year. It launched 23 Candere showrooms during Q3 FY 2025.
The company further said it plans to launch 30 Kalyan showrooms and 15 Candere showrooms in India during the current quarter, with an aim to stay ahead of its announced showroom roll-out plan of 80 Kalyan showrooms and 50 Candere showrooms in India for FY2025.
For FY 2026, the company has drawn up plans to launch 170 showrooms across Kalyan and Candere formats - 75 Kalyan showrooms (all FOCO) in non-south India, 15 Kalyan showrooms (all FOCO) across south India and international markets and 80 Candere showrooms in India.
8:50 AM
The resilience of the Pharma and health care stocks also indicate the influence of the virus concerns on the market. The fact that momentum stocks were on the back foot yesterday indicates lack of confidence by the bulls in the context of negative sentiments.
Clarification by the government that there is no room for undue concern from the virus, which is not new, can facilitate a rebound in the market, led by momentum stocks. Investors can use the dip to buy fundamentally strong beaten down stocks in automobiles and financials."
Views By: Dr. V K Vijayakumar, Chief Investment Strategist, Geojit Financial Services
Stock Market LIVE Updates: 'Investors can use dip to buy fundamentally strong beaten down auto & finance stks'
Stock Market LIVE Updates: "The 1.6 per cent cut in Nifty yesterday appears to be an overreaction to the HMPV virus concerns. FII selling of Rs 2,575 crores was overwhelmed by the DII buying of Rs 5,750 crores. In spite of that, the Nifty corrected by 388 points, which means the correction was triggered by short selling by bears trying to exploit the negative sentiments.
The resilience of the Pharma and health care stocks also indicate the influence of the virus concerns on the market. The fact that momentum stocks were on the back foot yesterday indicates lack of confidence by the bulls in the context of negative sentiments.
Clarification by the government that there is no room for undue concern from the virus, which is not new, can facilitate a rebound in the market, led by momentum stocks. Investors can use the dip to buy fundamentally strong beaten down stocks in automobiles and financials."
Views By: Dr. V K Vijayakumar, Chief Investment Strategist, Geojit Financial Services
8:46 AM
Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations. Sentynl’s NDA is supported by positive topline clinical efficacy results for CUTX-101, the company said in an exchange filing.
CUTX-101 was granted Breakthrough Therapy, Fast Track, Rare Pediatric Disease and Orphan Drug Designations by the FDA and Orphan Designation by the European Medicines Agency (EMA). Under the Prescription Drug User Fee Act (PDUFA), the FDA set a six-month period with a target action date of June 30, 2025, the company said.
In December 2023, Sentynl assumed full responsibility for the development and commercialisation of CUTX-101 from Cyprium Therapeutics, a Fortress subsidiary company focused on the development of novel therapies for the treatment of Menkes disease and related copper metabolism disorders.
Stock Market LIVE Updates: USFDA accepts Zydus Lifesciences' unit's Menkes disease drug for priority review
Stock Market LIVE Updates: — Zydus Lifesciences today informed that the US Food and Drug Administration (FDA) has accepted for filing and Priority review of its wholly-owned subsidiary, Sentynl Therapeutics and Fortress Biotech, Inc's New Drug Application (NDA) for CUTX-101, the product candidate for the treatment of Menkes disease.
Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations. Sentynl’s NDA is supported by positive topline clinical efficacy results for CUTX-101, the company said in an exchange filing.
CUTX-101 was granted Breakthrough Therapy, Fast Track, Rare Pediatric Disease and Orphan Drug Designations by the FDA and Orphan Designation by the European Medicines Agency (EMA). Under the Prescription Drug User Fee Act (PDUFA), the FDA set a six-month period with a target action date of June 30, 2025, the company said.
In December 2023, Sentynl assumed full responsibility for the development and commercialisation of CUTX-101 from Cyprium Therapeutics, a Fortress subsidiary company focused on the development of novel therapies for the treatment of Menkes disease and related copper metabolism disorders.
8:39 AM
The company, in an exchange filing, said, "The biosimilar Ustekinumab has been developed and manufactured by the Company and will be commercialised and marketed in Japan by the Company’s exclusive commercial partner, Yoshindo Inc".
Ustekinumab, a monoclonal antibody, is approved for the treatment of Psoriasis Vulgaris and Psoriatic Arthritis (PsA).
Stock Market LIVE Updates: Biocon gets Japanese health regulator, PMDA's nod for Psoriasis drug Ustekinumab BS
Stock Market LIVE Updates: Biocon Biologics today informed that the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan has approved Ustekinumab BS subcutaneous injection [YD], a biosimilar to the reference product, Stelara (Ustekinumab).
The company, in an exchange filing, said, "The biosimilar Ustekinumab has been developed and manufactured by the Company and will be commercialised and marketed in Japan by the Company’s exclusive commercial partner, Yoshindo Inc".
Ustekinumab, a monoclonal antibody, is approved for the treatment of Psoriasis Vulgaris and Psoriatic Arthritis (PsA).
8:33 AM
Stock Market LIVE Updates: Sebi eases settlement norms for brokerage accounts inactive over 30 days
Stock Market LIVE Updates: The Securities and Exchange Board of India (Sebi) on Monday relaxed settlement norms for brokerage accounts remaining inactive for more than 30 days. Brokers will now have to return the money lying in such idle accounts on a pre-decided settlement date every month.
Till now, brokers were required to return funds within three working days of identifying inactivity. READ MORE
8:31 AM
Stock Market LIVE Updates: Large-cap cut-off surpasses Rs 1 trillion as 11 new stocks join the list
Stock Market LIVE Updates: The 100-stock largecap basket of Mutual funds (MFs) has seen a major reshuffle in the latest semi-annual reclassification with seven midcap stocks and four new listings earning the largecap tag. READ MORE
8:30 AM
Stock Market LIVE Updates: Gold slumps Rs 10 to Rs 78,700, silver declines Rs 100 to Rs 91,400
Stock Market LIVE Updates: The price of 24-carat gold fell Rs 10 in early trade on Tuesday, with ten grams of the precious metal trading at Rs 78,700 according to the GoodReturns website. The price of silver also decreased by Rs 100, with one kilogram of the precious metal selling at Rs 91,400. The price of 22-carat gold also went down by Rs 10, with ten grams of the yellow metal selling at Rs 72,140. READ MORE
8:29 AM
Stock Market LIVE Updates: ARPUs to rise, user churn to subside for telcos in Q3FY25, say analysts
Stock Market LIVE Updates: Telecom operators (telcos) are expected to report continuing growth in average revenue per user (ARPU) in the third quarter (October-December) of the current financial year (Q3FY25), analysts believe. The impact of SIM (subscriber identity module) consolidation, as a result of July's tariff hike, is also expected to subside, they said. READ MORE
8:23 AM
Experts, however, say resilience in rural demand, along with sustained agricultural and services-sector output, will keep India on a growth path towards achieving 6.4-6.8 per cent expansion in FY25.
Stock Market LIVE Updates: India's FY25 GDP growth likely to remain in 6.4-6.8% range: Experts
Stock Market LIVE Updates: Three weeks before the Union Budget for FY26, the National Statistics Office will release the first advance estimates of gross domestic product (GDP) for FY25 on January 7 amid a moderation in growth expectations.
Experts, however, say resilience in rural demand, along with sustained agricultural and services-sector output, will keep India on a growth path towards achieving 6.4-6.8 per cent expansion in FY25.
The Reserve Bank of India (RBI) has lowered the growth projection for this financial year to 6.6 per cent from an earlier estimate of 7.2 per cent. READ MORE
Topics : MARKET WRAP MARKET LIVE MARKETS LIVE MARKETS TODAY stock market trading Markets Sensex Nifty S&P BSE Sensex BSE Sensex NSE Nifty Nifty50 Nifty 50 BSE NSE BSE NSE equity Equities Indian equities US equities Indian stock markets US stock markets Global stock markets Chinese stock market US markets Indian markets Asian markets Asia Markets IPO GMP IPO activity
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Jan 07 2025 | 7:52 AM IST
